<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00728364</url>
  </required_header>
  <id_info>
    <org_study_id>AFD-CKD-Austria-2008</org_study_id>
    <nct_id>NCT00728364</nct_id>
  </id_info>
  <brief_title>Anderson-Fabry Disease in Chronic Kidney Disease Patients Not on Renal Replacement Therapy</brief_title>
  <official_title>A Case Finding Study for Anderson-Fabry Disease Among Patients With Chronic Kidney Disease Not on Renal Replacement Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Klinikum Wels-Grieskirchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Klinikum Wels-Grieskirchen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anderson-Fabry disease is a rare X-linked lysosomal storage disorder due to the deficiency of
      alfa-galactosidase A (AGAL). The subsequent accumulation of glycosphingolipids may lead to to
      cardiac, renal, and central nervous system impairment as well as premature death. Recently
      published studies suggest that the true incidence of the disease may be underestimated in
      certain risk groups, e.g. in patients with chronic kidney disease (CKD).

      Therefore, the investigators initiated a multicenter case-finding study in Austria by
      screening patients with chronic kidney disease not yet on renal replacement therapy.
      Molecular isoforms of globotriaosylceramide (Gb3), characterized by different chain lengths
      of their N-acyl residues, will be determined in a urine sample. Characteristic parameters,
      including the ratio of C24/C18 isoforms will be used for identifying patients liable to have
      the disease. A positive result will be confirmed by biochemical and genetic testing.

      A sample size of 5.000 chronic kidney disease patients is envisaged allowing for detection of
      1 to 25 patients with Anderson-Fabry disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <enrollment type="Actual">4353</enrollment>
  <condition>Focus of Study: Prevalence of Fabry Disease in CKD Population</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with chronic kidney disease KDOQI stage 1-5 attending outpatient nephrology
        clinics in Austria and willing to participate
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chronic kidney disease KDOQI stage 1-5

          -  Informed consent

        Exclusion Criteria:

          -  Patients already on renal replacement therapy

          -  Not willing to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manfred Wallner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum Wels-Grieskirchen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum Wels-Grieskirchen</name>
      <address>
        <city>Wels</city>
        <state>Upper Austria</state>
        <zip>A-4600</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <results_reference>
    <citation>Kotanko P, Kramar R, Devrnja D, Paschke E, Voigtländer T, Auinger M, Pagliardini S, Spada M, Demmelbauer K, Lorenz M, Hauser AC, Kofler HJ, Lhotta K, Neyer U, Pronai W, Wallner M, Wieser C, Wiesholzer M, Zodl H, Födinger M, Sunder-Plassmann G. Results of a nationwide screening for Anderson-Fabry disease among dialysis patients. J Am Soc Nephrol. 2004 May;15(5):1323-9. Erratum in: J Am Soc Nephrol. 2004 Sep;15(9):A4. J Am Soc Nephrol. 2004 Aug;15(8):1a.</citation>
    <PMID>15100373</PMID>
  </results_reference>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2008</study_first_submitted>
  <study_first_submitted_qc>July 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2008</study_first_posted>
  <last_update_submitted>April 10, 2012</last_update_submitted>
  <last_update_submitted_qc>April 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Klinikum Wels-Grieskirchen</investigator_affiliation>
    <investigator_full_name>Manfred Wallner MD</investigator_full_name>
    <investigator_title>Consultant</investigator_title>
  </responsible_party>
  <keyword>Anderson Fabry disease</keyword>
  <keyword>chronic kidney disease</keyword>
  <keyword>prevalence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Fabry Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

